XML 119 R76.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Details)
1 Months Ended 12 Months Ended
Feb. 09, 2018
USD ($)
Feb. 09, 2018
EUR (€)
Aug. 31, 2014
USD ($)
Aug. 31, 2014
EUR (€)
Dec. 31, 2017
USD ($)
installment
Dec. 31, 2017
EUR (€)
installment
claim
Dec. 31, 2016
EUR (€)
Commitments and Contingencies              
Claims known to management related to activities of company | claim           0  
Research and development commitments | €           € 7,704,000 € 8,856,000
Less than 1 year              
Commitments and Contingencies              
Research and development commitments | €           6,094,000  
Patent license agreement              
Commitments and Contingencies              
Milestone payment on achievement of development and regulatory milestones         $ 700,000 584,000  
Annual license fee         $ 10,000 € 8,000  
Royalty obligation as a percentage of net sales         2.00% 2.00%  
Clinical support agreement | Cystic Fibrosis Foundation Therapeutics Inc              
Commitments and Contingencies              
Milestone payment on achievement of first commercial sale         $ 16,000,000 € 13,000,000  
Number of milestone payment installments | installment         3 3  
Contribution to support clinical development     $ 3,000,000 € 2,500,000      
Milestone payment on achievement of net sales exceeding threshold limit         $ 3,000,000 € 2,500,000  
Threshold sales for milestone payment         500,000,000 417,000,000  
Milestone payment on transfer, sells or licenses other than for clinical or development purposes         $ 6,000,000 € 5,000,000  
Period after first commercial sale for payment of first installment         90 days 90 days  
Clinical support agreement | Foundation Fighting Blindness              
Commitments and Contingencies              
Milestone payment on achievement of first commercial sale         $ 37,500,000 € 31,300,000  
Number of milestone payment installments | installment         4 4  
Milestone payment on transfer, sells or licenses other than for clinical or development purposes         $ 15,000,000 € 12,500,000  
Period after first commercial sale for payment of first installment         60 days 60 days  
Minimum              
Commitments and Contingencies              
Research And Commitments Period         1 year 1 year  
Maximum              
Commitments and Contingencies              
Research And Commitments Period         5 years 5 years  
Forecast | Entering into partnership | Clinical support agreement | Foundation Fighting Blindness              
Commitments and Contingencies              
Contribution to support clinical development $ 7,500,000 € 6,300,000